IL-22 is an α-helical cytokine. IL-22 binds to a heterodimeric cell surface receptor composed of IL-10R2 and IL-22R1 subunits. IL-22R is expressed on tissue cells, and it is absent on immune cells.
Crystallization is possible if the N-linked glycosylation sites are removed in mutants of IL-22 bound with high-affinity cell-surface receptor sIL-22R1. The crystallographic asymmetric unit contained two IL-22-sIL-22R1 complexes.
IL-22 a member of a group of cytokines called the IL-10 family or IL-10 superfamily (including IL-19, IL-20, IL-24, and IL-26), a class of potent mediators of cellular inflammatory responses. It shares use of IL-10R2 in cell signaling with other members of this family, IL-10, IL-26, IL-28A/B and IL-29. IL-22 is produced by activated DC and T cells and initiates innate immune responses against bacterial pathogens especially in epithelial cells such as respiratory and gut epithelial cells. IL-22 along with IL-17 is rapidly produced by splenic LTi-like cells  and also produced by Th17 cells and likely plays a role in the coordinated response of both adaptive innate immune systems, autoimmunity and tissue regeneration.
IL-22 biological activity is initiated by binding to a cell-surface complex composed of IL-22R1 and IL-10R2 receptor chains and further regulated by interactions with a soluble binding protein, IL-22BP, which shares sequence similarity with an extracellular region of IL-22R1 (sIL-22R1). IL-22 and IL-10 receptor chains play a role in cellular targeting and signal transduction to selectively initiate and regulate immune responses. IL-22 can contribute to immune disease through the stimulation of inflammatory responses, S100s and defensins. IL-22 also promotes hepatocyte survival in the liver and epithelial cells in the lung and gut similar to IL-10. In some contexts, the pro-inflammatory versus tissue-protective functions of IL-22 are regulated by the often co-expressed cytokine IL-17A 
IL-22, signals through the interferon receptor-related proteins CRF2-4 and IL-22R. It forms cell surface complexes with IL-22R1 and IL-10R2 chains resulting in signal transduction through receptor, IL-10R2. The IL-22/IL-22R1/IL-10R2 complex activates intracellular kinases (JAK1, Tyk2, and MAP kinases) and transcription factors, especially STAT3. It can induce IL-20 and IL-24 signaling when IL-22R1 pairs with IL-20R2.
^ abXie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J et al. (Oct 2000). "Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R". The Journal of Biological Chemistry275 (40): 31335–9. doi:10.1074/jbc.M005304200. PMID10875937.
^Witte K, Witte E, Sabat R, Wolk K (Aug 2010). "IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties". Cytokine & Growth Factor Reviews21 (4): 237–51. doi:10.1016/j.cytogfr.2010.04.002. PMID20655797.
^Hill T, Krougly O, Nikoopour E, Bellemore S, Lee-Chan E, Fouser LA et al. (2013). "The involvement of interleukin-22 in the expression of pancreatic beta cell regenerative Reg genes". Cell Regeneration2 (1): 2. doi:10.1186/2045-9769-2-2. PMID25408874.
Weger W, Hofer A, Wolf P, El-Shabrawi Y, Renner W, Kerl H et al. (Sep 2009). "Common polymorphisms in the interleukin-22 gene are not associated with chronic plaque psoriasis". Experimental Dermatology18 (9): 796–8. doi:10.1111/j.1600-0625.2009.00840.x. PMID19469905.
Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, Snippe H et al. (Apr 2010). "New genetic associations detected in a host response study to hepatitis B vaccine". Genes and Immunity11 (3): 232–8. doi:10.1038/gene.2010.1. PMID20237496.
de Moura PR, Watanabe L, Bleicher L, Colau D, Dumoutier L, Lemaire MM et al. (Apr 2009). "Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22". FEBS Letters583 (7): 1072–7. doi:10.1016/j.febslet.2009.03.006. PMID19285080.
Wong CK, Lun SW, Ko FW, Wong PT, Hu SQ, Chan IH et al. (2009). "Activation of peripheral Th17 lymphocytes in patients with asthma". Immunological Investigations38 (7): 652–64. doi:10.1080/08820130903062756. PMID19811428.
Shen H, Goodall JC, Hill Gaston JS (Jun 2009). "Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis". Arthritis and Rheumatism60 (6): 1647–56. doi:10.1002/art.24568. PMID19479869.
Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L (Aug 2010). "Interleukin-22 genetic polymorphisms and risk of colon cancer". Cancer Causes & Control21 (8): 1165–70. doi:10.1007/s10552-010-9542-5. PMID20339910.
Pan HF, Zhao XF, Yuan H, Zhang WH, Li XP, Wang GH et al. (Mar 2009). "Decreased serum IL-22 levels in patients with systemic lupus erythematosus". Clinica Chimica Acta; International Journal of Clinical Chemistry401 (1-2): 179–80. doi:10.1016/j.cca.2008.11.009. PMID19046958.
Liu Y, Yang B, Zhou M, Li L, Zhou H, Zhang J et al. (Jun 2009). "Memory IL-22-producing CD4+ T cells specific for Candida albicans are present in humans". European Journal of Immunology39 (6): 1472–9. doi:10.1002/eji.200838811. PMID19449309.
Sekikawa A, Fukui H, Suzuki K, Karibe T, Fujii S, Ichikawa K et al. (Mar 2010). "Involvement of the IL-22/REG Ialpha axis in ulcerative colitis". Laboratory Investigation; A Journal of Technical Methods and Pathology90 (3): 496–505. doi:10.1038/labinvest.2009.147. PMID20065946.
He M, Liang P (Feb 2010). "IL-24 transgenic mice: in vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis". Journal of Immunology184 (4): 1793–8. doi:10.4049/jimmunol.0901829. PMID20061404.
Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S et al. (Dec 2009). "The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis". European Journal of Immunology39 (12): 3570–81. doi:10.1002/eji.200939687. PMID19830738.
Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LV et al. (Nov 2009). "IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion". Journal of Immunology183 (10): 6639–45. doi:10.4049/jimmunol.0902587. PMID19864591.
Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK et al. (Feb 2009). "A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity". Nature457 (7230): 722–5. doi:10.1038/nature07537. PMID18978771.